Table 5.
Summary of pathway enrichment analyses
| Pathway | Genes Found in the Pathway | # Gene in Pathway | # Gene Observed | # Gene Expected | Observed/Expected Ratio | Raw p-Value | Adjusted p-Value |
|---|---|---|---|---|---|---|---|
| Neuroactive ligand- receptor interaction | CHRNA3,CHRNA4,CHRNA5,CHRNA6, CHRNB3,CHRNB4,GABRG3,GRM5, SSTR1,SSTR4,THRB | 272 | 11 | 1.65 | 6.66 | 1.03E-06 | 5.56E-05 |
| Endocytosis | AP2A2,EHD3,FGFR2,IQSEC1,MET,RAB5C | 201 | 6 | 1.22 | 4.91 | 0.0015 | 0.0405 |
| Intestinal immune network for IgA production | HLA-DMB,HLA-DRB5,IL15 | 48 | 3 | 0.29 | 10.29 | 0.0031 | 0.0540 |
| Lysosome | AP1S3,LIPA,MANBA,SUMF1 | 121 | 4 | 0.74 | 5.44 | 0.0065 | 0.0694 |
| Protein export | SPCS3,SRP9 | 23 | 2 | 0.14 | 14.31 | 0.0086 | 0.0694 |
| Cell adhesion molecules (CAMs) | CDH4,HLA-DMB,HLA-DRB5,NRCAM | 133 | 4 | 0.81 | 4.95 | 0.0090 | 0.0694 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | CACNA1D,CACNG4,CTNNA3 | 74 | 3 | 0.45 | 6.67 | 0.0105 | 0.0709 |
| Dilated cardiomyopathy | ADCY4,CACNA1D,CACNG4 | 90 | 3 | 0.55 | 5.49 | 0.0177 | 0.0816 |
| Purine metabolism | ADCY4,PAPSS2,PDE2A,PDE4B | 162 | 4 | 0.98 | 4.06 | 0.0174 | 0.0816 |
| Huntington’s disease | AP2A2,GRM5,PPARG,TAF4 | 183 | 4 | 1.11 | 3.60 | 0.0259 | 0.0816 |
| MAPK signaling pathway | CACNA1D,CACNG4,DUSP16,FGFR2,MRAS | 268 | 5 | 1.63 | 3.07 | 0.0244 | 0.0816 |
| Melanogenesis | ADCY4,FZD8,WNT16 | 101 | 3 | 0.61 | 4.89 | 0.0239 | 0.0816 |
| Allograft rejection | HLA-DMB,HLA-DRB5 | 37 | 2 | 0.22 | 8.90 | 0.0213 | 0.0816 |
| Type I diabetes mellitus | HLA-DMB,HLA-DRB5 | 43 | 2 | 0.26 | 7.66 | 0.0282 | 0.0816 |
| Asthma | HLA-DMB,HLA-DRB5 | 30 | 2 | 0.18 | 10.97 | 0.0143 | 0.0816 |
| Graft-versus-host disease | HLA-DMB,HLA-DRB5 | 41 | 2 | 0.25 | 8.03 | 0.0258 | 0.0816 |
| Rheumatoid arthritis | HLA-DMB,HLA-DRB5,IL15 | 91 | 3 | 0.55 | 5.43 | 0.0182 | 0.0816 |
| Chemokine signaling pathway | ADCY4,TIAM2,VAV2,XCL1 | 189 | 4 | 1.15 | 3.48 | 0.0287 | 0.0816 |
| Regulation of actin cytoskeleton | FGFR2,MRAS,TIAM2,VAV2 | 213 | 4 | 1.29 | 3.09 | 0.0416 | 0.0944 |
| Autoimmune thyroid disease | HLA-DMB,HLA-DRB5 | 52 | 2 | 0.32 | 6.33 | 0.0400 | 0.0944 |
| Hedgehog signaling pathway | RAB23,WNT16 | 56 | 2 | 0.34 | 5.88 | 0.0457 | 0.0944 |
| Basal cell carcinoma | FZD8,WNT16 | 55 | 2 | 0.33 | 5.99 | 0.0442 | 0.0944 |
| Tight junction | CTNNA3,EPB41L1,MRAS | 132 | 3 | 0.8 | 3.74 | 0.0469 | 0.0944 |
| Inositol phosphate metabolism | IMPA1,MINPP1 | 57 | 2 | 0.35 | 5.78 | 0.0472 | 0.0944 |
| Axon guidance | MET,NTNG1,ROBO2 | 129 | 3 | 0.78 | 3.83 | 0.0443 | 0.0944 |
| Staphylococcus aureus infection | HLA-DMB,HLA-DRB5 | 55 | 2 | 0.33 | 5.99 | 0.0442 | 0.0944 |
Statistically significant adjusted p-values are highlighted in bold.